StreetInsider.com News Articles

Form 10-Q Enveric Biosciences, For: Jun 30

Fri, 14 Aug 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260814/26931203.html

Form 10-Q Enveric Biosciences, For: Jun 30

Fri, 14 Aug 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260814/26931203.html

Form 8-K Enveric Biosciences, For: Aug 14

Fri, 14 Aug 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260814/26930951.html

Form 8-K Enveric Biosciences, For: Aug 14

Fri, 14 Aug 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260814/26930951.html

Form SCHEDULE 13G/A Enveric Biosciences, Filed by: Lind Global Fund III LP

Fri, 14 Aug 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260814/26930523.html

Form SCHEDULE 13G/A Enveric Biosciences, Filed by: Lind Global Fund III LP

Fri, 14 Aug 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260814/26930523.html

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026

Fri, 14 Aug 2026 16:05:00 -0400

EB-003 Development Highlights:

Continued advancing IND-enabling studies supporting the planned submission of an Investigational New Drug (IND) application for EB-003 and expected initiation of Phase 1 clinical trial
Reported preclinical data demonstrating that EB-003 consistently exhibited a non-hallucinogenic profile in a highly sensitive GloSensor™ assay, complementing previously reported BRET assay findings
Announced promising results from preclinical in vitro experiments indicating no photoreactive potential for EB-003, further derisking its continued development as a potential treatment of neuropsychiatric disorders
Initiated genotoxicity studies to evaluate the potential for EB-003 to interact with DNA and cause genetic mutations, a critical measure of safety required for IND submission

Corporate

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026

Fri, 14 Aug 2026 16:05:00 -0400

EB-003 Development Highlights:

Continued advancing IND-enabling studies supporting the planned submission of an Investigational New Drug (IND) application for EB-003 and expected initiation of Phase 1 clinical trial

Reported preclinical data demonstrating that EB-003 consistently exhibited a non-hallucinogenic profile in a highly sensitive GloSensor™ assay, complementing previously reported BRET assay findings

Announced promising results from preclinical in vitro experiments indicating no photoreactive potential for EB-003, further derisking its continued development as a potential treatment of neuropsychiatric disorders

Initiated genotoxicity studies to evaluate the potential for EB-003 to interact with DNA and cause genetic mutations, a critical measure of safety required for IND submission

Corporate

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026

Fri, 14 Aug 2026 16:05:00 -0400

EB-003 Development Highlights:

Continued advancing IND-enabling studies supporting the planned submission of an Investigational New Drug (IND) application for EB-003 and expected initiation of Phase 1 clinical trial

Reported preclinical data demonstrating that EB-003 consistently exhibited a non-hallucinogenic profile in a highly sensitive GloSensor™ assay, complementing previously reported BRET assay findings

Announced promising results from preclinical in vitro experiments indicating no photoreactive potential for EB-003, further derisking its continued development as a potential treatment of neuropsychiatric disorders

Initiated genotoxicity studies to evaluate the potential for EB-003 to interact with DNA and cause genetic mutations, a critical measure of safety required for IND submission

Corporate

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026

Fri, 14 Aug 2026 16:05:00 -0400

EB-003 Development Highlights:

Continued advancing IND-enabling studies supporting the planned submission of an Investigational New Drug (IND) application for EB-003 and expected initiation of Phase 1 clinical trial

Reported preclinical data demonstrating that EB-003 consistently exhibited a non-hallucinogenic profile in a highly sensitive GloSensor™ assay, complementing previously reported BRET assay findings

Announced promising results from preclinical in vitro experiments indicating no photoreactive potential for EB-003, further derisking its continued development as a potential treatment of neuropsychiatric disorders

Initiated genotoxicity studies to evaluate the potential for EB-003 to interact with DNA and cause genetic mutations, a critical measure of safety required for IND submission

Corporate

Form SCHEDULE 13G Enveric Biosciences, Filed by: ARMISTICE CAPITAL, LLC

Fri, 14 Aug 2026 10:11:00 -0400
si-local-file:///var/storage/secattach/20260814/26926190.html

Form SCHEDULE 13G Enveric Biosciences, Filed by: ARMISTICE CAPITAL, LLC

Fri, 14 Aug 2026 10:11:00 -0400
si-local-file:///var/storage/secattach/20260814/26926190.html

Form SCHEDULE 13G/A Enveric Biosciences, Filed by: Ayrton Capital LLC

Thu, 13 Aug 2026 12:41:00 -0400
si-local-file:///var/storage/secattach/20260813/26919206.html

Form SCHEDULE 13G/A Enveric Biosciences, Filed by: Ayrton Capital LLC

Thu, 13 Aug 2026 12:41:00 -0400
si-local-file:///var/storage/secattach/20260813/26919206.html

Enveric preclinical data backs non-hallucinogenic profile of EB-003

Wed, 05 Aug 2026 08:00:18 -0400

Enveric Biosciences (NASDAQ: ENVB) announced new preclinical data supporting the non-hallucinogenic profile of its lead drug candidate, EB-003, according to a company press release.

The study used a GloSensor™ cAMP assay, a live-cell test designed to detect Gi-coupled receptor responses in real time. EB-003 was evaluated alongside known hallucinogenic and non-hallucinogenic reference compounds, with results the company says are consistent with research published in Nature in 2026 (Xu et al.), which linked 5-HT2A receptor-mediated Gi activation to hallucinogenic compounds. In the company's evaluations, EB-003 fell within the non-hallucinogenic range.

The new findings complement previously reported BRET assay results, which the company says

Enveric preclinical data backs non-hallucinogenic profile of EB-003

Wed, 05 Aug 2026 08:00:18 -0400

Enveric Biosciences (NASDAQ: ENVB) announced new preclinical data supporting the non-hallucinogenic profile of its lead drug candidate, EB-003, according to a company press release.

The study used a GloSensor™ cAMP assay, a live-cell test designed to detect Gi-coupled receptor responses in real time. EB-003 was evaluated alongside known hallucinogenic and non-hallucinogenic reference compounds, with results the company says are consistent with research published in Nature in 2026 (Xu et al.), which linked 5-HT2A receptor-mediated Gi activation to hallucinogenic compounds. In the company's evaluations, EB-003 fell within the non-hallucinogenic range.

The new findings complement previously reported BRET assay results, which the company says

Enveric preclinical data backs non-hallucinogenic profile of EB-003

Wed, 05 Aug 2026 08:00:18 -0400

Enveric Biosciences (NASDAQ: ENVB) announced new preclinical data supporting the non-hallucinogenic profile of its lead drug candidate, EB-003, according to a company press release.

The study used a GloSensor™ cAMP assay, a live-cell test designed to detect Gi-coupled receptor responses in real time. EB-003 was evaluated alongside known hallucinogenic and non-hallucinogenic reference compounds, with results the company says are consistent with research published in Nature in 2026 (Xu et al.), which linked 5-HT2A receptor-mediated Gi activation to hallucinogenic compounds. In the company's evaluations, EB-003 fell within the non-hallucinogenic range.

The new findings complement previously reported BRET assay results, which the company says

Enveric preclinical data backs non-hallucinogenic profile of EB-003

Wed, 05 Aug 2026 08:00:18 -0400

Enveric Biosciences (NASDAQ: ENVB) announced new preclinical data supporting the non-hallucinogenic profile of its lead drug candidate, EB-003, according to a company press release.

The study used a GloSensor™ cAMP assay, a live-cell test designed to detect Gi-coupled receptor responses in real time. EB-003 was evaluated alongside known hallucinogenic and non-hallucinogenic reference compounds, with results the company says are consistent with research published in Nature in 2026 (Xu et al.), which linked 5-HT2A receptor-mediated Gi activation to hallucinogenic compounds. In the company's evaluations, EB-003 fell within the non-hallucinogenic range.

The new findings complement previously reported BRET assay results, which the company says

Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003

Wed, 05 Aug 2026 08:00:00 -0400

GloSensor™ assay findings align with previously reported BRET assay data as EB-003 advances toward planned Phase 1 clinical development

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced new preclinical data that further supports the growing body of evidence reinforcing the non-hallucinogenic profile of its lead candidate, EB-003.
Preclinical testing of EB-003 was conducted using a targeted, highly sensitive GloSensor™ cAMP assay, which has been previously described in peer-reviewed scientific literature (Wang et al., 2022)1. The Promega

Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003

Wed, 05 Aug 2026 08:00:00 -0400

GloSensor™ assay findings align with previously reported BRET assay data as EB-003 advances toward planned Phase 1 clinical development

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced new preclinical data that further supports the growing body of evidence reinforcing the non-hallucinogenic profile of its lead candidate, EB-003.
Preclinical testing of EB-003 was conducted using a targeted, highly sensitive GloSensor™ cAMP assay, which has been previously described in peer-reviewed scientific literature (Wang et al., 2022)1. The Promega

Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003

Wed, 05 Aug 2026 08:00:00 -0400

GloSensor™ assay findings align with previously reported BRET assay data as EB-003 advances toward planned Phase 1 clinical development

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced new preclinical data that further supports the growing body of evidence reinforcing the non-hallucinogenic profile of its lead candidate, EB-003.
Preclinical testing of EB-003 was conducted using a targeted, highly sensitive GloSensor™ cAMP assay, which has been previously described in peer-reviewed scientific literature (Wang et al., 2022)1. The Promega

Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003

Wed, 05 Aug 2026 08:00:00 -0400

GloSensor™ assay findings align with previously reported BRET assay data as EB-003 advances toward planned Phase 1 clinical development

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced new preclinical data that further supports the growing body of evidence reinforcing the non-hallucinogenic profile of its lead candidate, EB-003.
Preclinical testing of EB-003 was conducted using a targeted, highly sensitive GloSensor™ cAMP assay, which has been previously described in peer-reviewed scientific literature (Wang et al., 2022)1. The Promega

Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003

Wed, 05 Aug 2026 08:00:00 -0400

GloSensor™ assay findings align with previously reported BRET assay data as EB-003 advances toward planned Phase 1 clinical development

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced new preclinical data that further supports the growing body of evidence reinforcing the non-hallucinogenic profile of its lead candidate, EB-003.
Preclinical testing of EB-003 was conducted using a targeted, highly sensitive GloSensor™ cAMP assay, which has been previously described in peer-reviewed scientific literature (Wang et al., 2022)1. The Promega

Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003

Wed, 05 Aug 2026 08:00:00 -0400

GloSensor™ assay findings align with previously reported BRET assay data as EB-003 advances toward planned Phase 1 clinical development

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced new preclinical data that further supports the growing body of evidence reinforcing the non-hallucinogenic profile of its lead candidate, EB-003.
Preclinical testing of EB-003 was conducted using a targeted, highly sensitive GloSensor™ cAMP assay, which has been previously described in peer-reviewed scientific literature (Wang et al., 2022)1. The Promega

Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003

Wed, 05 Aug 2026 08:00:00 -0400

GloSensor™ assay findings align with previously reported BRET assay data as EB-003 advances toward planned Phase 1 clinical development

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced new preclinical data that further supports the growing body of evidence reinforcing the non-hallucinogenic profile of its lead candidate, EB-003.
Preclinical testing of EB-003 was conducted using a targeted, highly sensitive GloSensor™ cAMP assay, which has been previously described in peer-reviewed scientific literature (Wang et al., 2022)1. The Promega